CollPlant Biotechnologies Ltd (CLGN)
NASDAQ: CLGNHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
CLGN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $7.51M
- EPS (TTM)
- -$9.33
- Dividend yield
- None
- 52-week range
- 2.64 – 26.80
- Day range
- 3.31 – 4.16
- Volume / Avg
- 56.94K / 351.98K
- Beta
- —
- Shares outstanding
- 1.89M
- Next earnings
- Nov 25, 2026
52-week range
CLGN stock today
On Oct 8, CLGN ended the session at $3.97, adding $0.51 (14.74%), versus the S&P 500's 0.47% decline. Trading was light, with 56.94K shares changing hands, about 16% of the average daily volume. At this level, CLGN sits near the bottom of its 52-week range of $2.64 to $26.80: 85.2% below the high and 50.4% above the low.
CollPlant Biotechnologies has posted a net loss over the last twelve months (EPS of -$9.33), so its P/E ratio is not meaningful. CollPlant Biotechnologies's next earnings report is expected on Nov 25, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About CollPlant Biotechnologies
Company profileCollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. The company offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; Collage, a combinant human Collagen type I solution; VergenixSTR, a soft tissue matrix for the treatment of tendinopathy; and VergenixFG, a wound care product for the treatment of deep surgical incisions and deep wounds.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Yehiel Tal
- Headquarters
- Rehovot
- Employees
- 39
- Website
- collplant.com
Earnings
Earnings history- Next report
- Nov 25, 2026
CollPlant Biotechnologies peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SNGXSoligenix Inc. | 0.3466 | -1.95% | $7.54M | vs CLGN |
| CURXCuranex Pharmaceuticals Inc | 4.76 | -0.94% | $7.46M | vs CLGN |
| LGVNLongeveron Inc. Class A | 2.37 | -2.87% | $7.56M | vs CLGN |
| SKYESkye Bioscience Inc. | 1.68 | +1.82% | $7.44M | vs CLGN |
| TRAWTraws Pharma Inc. | 0.4803 | +0.27% | $7.38M | vs CLGN |
| FBLGFibroBiologics Inc. | 1.11 | -2.63% | $7.72M | vs CLGN |
| CNSPCNS Pharmaceuticals Inc. | 5.35 | -1.47% | $7.82M | vs CLGN |
| AIMAIM ImmunoTech Inc. | 0.1796 | -1.75% | $7.17M | vs CLGN |
Indexes, lists and sector
Appears in lists
CollPlant Biotechnologies stock FAQ
What is CollPlant Biotechnologies's stock price today?
CLGN last traded at $3.97 as of Oct 8, 4:00 PM EDT, up 14.74% on the day. Prices are delayed at least 15 minutes.
When is CollPlant Biotechnologies's next earnings date?
CollPlant Biotechnologies is expected to report earnings on Wednesday, November 25, 2026.
Who is CollPlant Biotechnologies's CEO?
Mr. Yehiel Tal is the chief executive officer of CollPlant Biotechnologies Ltd, which has about 39 employees.
What is the CLGN 52-week high?
The 52-week high for CLGN is $26.80 and the 52-week low is $2.64. The stock is currently 85.2% below its high.